1.	Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: MT2006-13, 0607M89052, UMN-MT2006-13, NCT00630565
2.	Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: J1227, NA_00071844, NCT01588951
3.	Stem Cell Transplant for Hematological Malignancy Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
4.	Phase III Randomized Study of Filgrastim (G-CSF)-Mobilized Matched-Sibling Donor Peripheral Blood Stem Cell Transplantation Versus G-CSF-Stimulated Matched-Sibling Donor Bone Marrow Transplantation in Patients With Hematologic Malignancies or Other Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
5.	Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML Phase: Phase III Type: Treatment Status: Active Age: 50 to 75 Sponsor: Other Protocol IDs: BMT190, 97843, 5567, NCT00568633
6.	Randomized Allogeneic Azacitidine Study Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2008-0503, NCT00887068
7.	TK008: Efficacy Study on the Strategy of Herpes Simplex Virus Thymidine Kinase Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TK008, 2009-012973-37, NCT00914628
8.	Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 60 and over Sponsor: NCI, Other Protocol IDs: CDR0000659585, ECOG-E2906, E2906, NCT01041703
9.	Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VOS-AML-301, 2010-021961-61, NCT01191801
10.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
11.	A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: 70 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CYC682-12, NCT01303796
12.	Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: 709, U01HL069294, U01HL069294-05, 0901, NCT01339910
13.	Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 30 Sponsor: NCI Protocol IDs: NCI-2011-02670, AAML1031, U10CA098543, COG-AAML1031, NCT01371981
14.	PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: PRO#1278: Flu-Bu-TBI, NCT01366612
15.	Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase: Phase III Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: 2011-0628, NCT01471444
16.	Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101) Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: 715, 2U10HL069294-11, NCT01597778
17.	Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: 60 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: CLTR0310-301, NCT01696084
18.	Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 15 to 60 Sponsor: NCI Protocol IDs: NCI-2013-00490, S1203, SWOG-S1203, U10CA032102, NCT01802333
19.	Stem Cell Transplant for Hematologic Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
20.	Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers Phase: Phase II, Phase I Type: Treatment Status: Active Age: 12 to 60 Sponsor: Pharmaceutical / Industry Protocol IDs: CB001, UMN-2003LS055, UMN-MT2003-20, VIACELL-CB001-03, UMN-0310M3141, NCT00089596
21.	Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
22.	Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
23.	DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000511032, S-WHITE-22304, S-WHITE-050047, 50047, NCT00397579
24.	Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 2005-0508, NCT00402558
25.	Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 55 Sponsor: NCI, Other Protocol IDs: 06-125, MSKCC-06125, NCT00423514